核心医疗科创板IPO获受理，系科创板第五套上市标准重启后首家创新医疗器械公司

Core Insights - Shenzhen Core Medical Technology Co., Ltd. has received acceptance for its IPO application on the Sci-Tech Innovation Board, marking it as the first innovative medical device company to be accepted under the fifth set of listing standards since their reactivation [1][2] - The company focuses on providing comprehensive, innovative, and high-quality artificial heart products, addressing significant clinical needs in acute and chronic heart failure [1] - Core Medical has achieved key milestones and is expected to have a market value of no less than 4 billion yuan, with its main products requiring approval from relevant national authorities [1] Company Overview - Core Medical is dedicated to the iterative upgrade of artificial heart products through original innovation and key core technology breakthroughs [1] - The company meets the listing criteria outlined in the "Listing Rules," specifically requiring at least one core product to have obtained approval for Phase II clinical trials [1] Industry Context - The acceptance of Core Medical's IPO application highlights the growing market space and potential for innovative medical device companies within the healthcare sector [1][2]